Representative Issuers

Charlie has represented companies/investment banks on capital market transactions involving issuers across industries, such as: Accelerate, Advaxis, Aerohive Networks, Agenus, Akari, Akcea, Akero, Allogene, Alteryx, Amedica, Amylin, Anadys, AnaptysBio, Anthera, Apigee, Arcadia, Arcus, Ardea, Arena, Aridis, Ascendis, ASLAN, Audentes, AutoGenomics, Ballast Point Brewing & Spirits, Cadence, Castlight, Cerus, Cidara, Corcept, Crinetics, Cyan, Cytori, Dermira, Dynavax, eBay, Eidos, Entropic Communications, Evofem, FireEye, Five Prime, Gemphire, Genomatica, Global Blood Therapeutics, Gossamer, Gritstone, Guardant Health, Halozyme, Health Catalyst, HealthEquity, Horizon, Ignyta, Immune Design, IMV, Inovio, Insys, Invitae, Ionis, Iterum, Jazz Pharmaceuticals, Kamada, Kite Pharma, Landry's, LifeLock, Limelight Networks, Livongo, MannKind, Medallia, MethylGene, Metropark, MindBody, Minerva, Mirati, NantHealth, NantKwest, Nektar, Neon, Neurocrine, ObsEva, Ooma, Optimer, Otonomy, Pernix, Poseida, PRA Holdings, Progressive Gaming, ProNAi, ProQR, Proto Labs, Quidel, Radiant Systems, Raptor Pharmaceutical, Reata, Receptos, Regulus, ReSearch Pharmaceutical Services, Sangamo, Santarus, Seattle Genetics, Senomyx, Sequenom, ShockWave, Sierra Oncology, Somaxon, Strongbridge, Surface Oncology, Sutro, Syndax, Tableau Software, Tabula Rasa, Taiwan Liposome Company, Tangoe, TRACON, Tricida, Trius, TriVascular Technologies, Uber Technologies, Verenium, Verona, Vical, Viewray, Vital Therapies, Xencor, Xenon, XenoPort, Zealand Pharma, Zscaler and Zymeworks.